ReviewUnited European gastroenterology journal2024
Recent advances in the treatment of refractory gastrointestinal angiodysplasia.
Review in United European gastroenterology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Taiwan practical consensus for evaluation and management of small-bowel bleeding.Journal of the Chinese Medical Association : JCMA · 2026Guideline
- Endoscopic Application of Tranexamic Acid and Sucralfate in Upper Gastrointestinal Bleeding: A Randomized Controlled Trial.Clinical and translational gastroenterology · 2026Trial
- Undetected Gastric Angiodysplastic Lesion Causing Obscure Gastrointestinal Bleeding.The Korean journal of helicobacter and upper gastrointestinal research · 2026Article
- Right Hemicolectomy for Refractory Hematochezia in Cecal Angiodysplasia After Failed Embolization: A Case Report.Cureus · 2026Article
- Angiodysplasia as a rare cause of acute hematochezia in a 33-year-old with vascular risk factors: a case report.Frontiers in medicine · 2026Article
- Sirolimus and gastrointestinal angiodysplasia: Can an established agent change the way gastrointestinal bleeding is managed?World journal of gastroenterology · 2025Article
- Management of gastrointestinal bleed in the intensive care setting, an updated literature review.World journal of critical care medicine · 2025Review
- Heyde Syndrome Unveiled: A Case Report with Current Literature Review and Molecular Insights.International journal of molecular sciences · 2024Review
- Recent advances in the treatment of refractory gastrointestinal angiodysplasia.United European gastroenterology journal · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal angiodysplasia (GIA) is a common, acquired, vascular abnormality of the digestive tract, and a frequent cause of bleeding. Refractory GIA criteria usually include recurrent bleeding, transfusions and/or repeat endoscopy. Pharmacological and interventional treatments have been the subject of recent high-quality publications. This review provides an overview of the latest updates on non-endoscopic management of refractory GIA. Aortic valve replacement has shown its efficacy in Heyde syndrome and should be considered if indicated. Anti-angiogenic drugs, such as Octreotide and Thalidomide, are efficient treatments of refractory GIA-related bleeding. Somatostatin analogs should, based on efficacy and tolerance profile, be considered first. In the future, a better understanding of the physiopathology of GIA might help develop new-targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.